19 -9 (71) 2024 - Sultonova G.Y., Akhmedova M. J. - STUDYING THE CHARACTERISTICS OF HEPATIC ENCEPHALOPATHY ARISING UPON LIVER CIRRHOSIS OF VIRAL ETIOLOGY IN CONNECTION WITH INTESTINAL DYSBIOSIS

STUDYING THE CHARACTERISTICS OF HEPATIC ENCEPHALOPATHY ARISING UPON LIVER CIRRHOSIS OF VIRAL ETIOLOGY IN CONNECTION WITH INTESTINAL DYSBIOSIS

Sultonova G.Y. - Tashkent Medical Academy

Akhmedova M. J. - Tashkent Medical Academy

Resume

The pathogenesis of hepatic encephalopathy (HE) is a complex multi-organ process, including a multi-level interaction between the development of chronic liver diseases, changes in the intestinal microflora and HE itself. As the severity of intestinal dysbiosis increases, the number of pathogenic microorganisms in the intestines increases, which leads to an increase in the level of ammonia in the blood serum of patients. This increase in ammonia concentration is associated with increased hepatic encephalopathy.

Key words: liver cirrhosis, hepatic encephalopathy, intestinal dysbiosis

First page

97

Last page

103

For citation:Sultonova G.Y., Akhmedova M. J. - STUDYING THE CHARACTERISTICS OF HEPATIC ENCEPHALOPATHY ARISING UPON LIVER CIRRHOSIS OF VIRAL ETIOLOGY IN CONNECTION WITH INTESTINAL DYSBIOSIS//New Day in Medicine 9(71)2024 97-103 https://newdayworldmedicine.com/en/new_day_medicine/9-71-2024

List of References

1. Ахмедова М.Д., Султонова Г.Ю., Бектимиров А.М.-Т. Состояние микрофлоры кишечника у больных циррозом печени вирусной этиологии, и коррекция его лечения. //ВИЧ-инфекция и иммуносупрессия. 2021 г., июнь;13(1):97-105.
2. Bajaj J.S.; Pinkerton S.D.; Sanyal A.J.; Heuman D.M. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: A cost-effectiveness analysis. //Hepatology. 2012 Sept; 55:1164-1171.
3. Carrat F. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. //Lancet (London, England), 2019 Mar;393(10179):1453-1464.
4. Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. //World J. Hepatol. 2015;7:425-442.
5. Younossi ZM, Golabi P, Henry L. A Comprehensive Review of Patient-reported Outcomes in Patients with Chronic Liver Diseases. //J Clin Gastroenterol. 2019;53(5):331-341.
6. Zhou J., Zhou F., Wang W., Zhang X.J., Ji Y.X., Zhang P. et al. Epidemiological feature of NAFLD from 1999 to 2018 in China. //Hepatology. 2020;71(5)/18:51-64.
7. Sharma B.C., Lunia M.K., Sharma P., Sachdeva S., Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: A randomized controlled trial. Clin. Gastroenterol. Hepatol. 2014;12:1003-1008.
8. Ubeda C.; Djukovic, A.; Isaac, S. Roles of the intestinal microbiota in pathogen protection. //Clin. Transl. Immunol. 2017;69-128.
9. Tilg H., Cani P.D., Mayer E.A. Gut microbiome and liver diseases. Gut 2016;65:2035-2044.
10. Schnabl B., Brenner D.A. Interactions between the intestinal microbiome and liver diseases. //Gastroenterology 2014;146:1513–1524.

    file

    download